pancreatic-cancer
9 stories tagged "pancreatic-cancer"
A 443,451-Cell Map Finds Pancreatic Tumors Are Crowds, Not Types
Inside one pancreatic tumor, NYU and UC San Diego researchers found as many as 11 distinct clones, which muddies the subtype label used to choose chemotherapy. The drug targets they point to next arrive with a history.
CancerMayo's Pancreatic Cancer AI Also Flags One Cancer-Free Scan in Five
Mayo's REDMOD caught 73 percent of pancreatic cancers on CT scans taken months before diagnosis, nearly double the radiologists' rate. It also flagged about 19 percent of cancer-free scans, and its lead researcher says it has not been tested at deployment prevalence.
CancerA Generic Vitamin D Drug Quadrupled Chemo Responses in a Small Pancreatic Cancer Trial, and Its Phase 2 Never Ran
Forty-two percent of patients on paricalcitol plus chemo saw their tumors shrink, versus 9 percent on placebo, in a 36-person safety trial. The randomized phase 2 meant to follow it never ran.
CancerThe Study Breaking Pancreatic Cancer's 'Shield' Was Co-Written by the Drug's Maker
The 'breakthrough' bought engineered mice eleven extra days, its headline human numbers come from a post-hoc subgroup, and one author is the chief scientist of the company that makes the drug.
CancerTwenty People, No Control Arm, and a Startup on the Side: Reading the Pancreatic Cancer Vaccine's Fine Print
Ninety percent of twenty volunteers made KRAS-specific T cells. None was shown to avoid cancer. Two of the investigators co-founded the company that licensed the shot from Johns Hopkins, which stands to collect royalties.
Drugs & FDAThe Pancreatic-Cancer Pill That Doubles Survival: $39,800 a Month, and a Fast Lane Congress Never Approved
Rasonque roughly doubles median survival in metastatic pancreatic cancer. Revolution Medicines priced it at $477,600 a year, more than double Keytruda, and the FDA cleared it early through a voucher program lawmakers say Congress never authorized.
CancerThe Cancer Trials That Buried Vitamin C Never Put It in a Vein
Mayo's famous trials gave advanced cancer patients vitamin C by mouth and found nothing. A randomized trial that delivered it by IV, at a dose pills cannot reach, doubled survival in metastatic pancreatic cancer.
CancerPancreatic cancer's undruggable wall just cracked. The follow-up is 8.5 months and the money was already placed.
Revolution Medicines' daraxonrasib nearly doubled median overall survival versus chemotherapy in previously treated metastatic pancreatic cancer at ASCO 2026, with 8.5 months of follow-up and a two-billion-dollar Royalty Pharma deal already riding on what comes next.
Nutrition & FoodYale's Olive Oil Cancer Story Did Not Actually Test Olive Oil
A Yale mouse study reported in Cancer Discovery is being sold as proof that olive oil fuels pancreatic cancer. The lab fed the mice purified oleic acid, the effect only showed up in males, and no one has tested it in a person.